Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024

有効成分の世界市場:予測及び分析 2020-2024

◆タイトル:Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR40608
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年12月
◆ページ数:156
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本レポートは、有効成分の市場実態を調査・分析し、エグゼクティブサマリー、レポートの範囲、市場状況、市場規模、ファイブフォース分析、顧客状況、製造タイプ別(キャプティブAPI、コントラクトAPI)分析、地域別状況、意思決定フレームワーク、市場の要因と課題、市場動向、企業状況、企業分析を掲載しています。
・エグゼクティブサマリー
・レポートの範囲
・市場状況
・市場規模
・ファイブフォース分析
・顧客状況
・有効成分の世界市場:製造タイプ別(キャプティブAPI、コントラクトAPI)
・地域別状況
・意思決定フレームワーク
・市場の要因と課題
・市場動向
・企業状況
・企業分析

Global Active Pharmaceutical Ingredients Market: About this market
Technavio’s active pharmaceutical ingredients market analysis considers sales from captive API and contract API. Our study also finds the sales of active pharmaceutical ingredients in Asia, Europe, North America, and ROW. In 2019, the contract API segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing demand for low-cost drugs will play a significant role in the contract API segment to maintain its market position. Also, our global active pharmaceutical ingredients market report looks at factors such as evolving API manufacturing scenarios in developing countries, increasing the number of type II drug master (DMFs), and growing need to focus on core competencies. However, growing concerns regarding outsourced APIs and capacity utilization constraints may hamper the growth of the active pharmaceutical ingredients industry over the forecast period.

Global Active Pharmaceutical Ingredients Market: Overview
Increasing number of type II drug master files (DMFs)
The market has witnessed a steady rise in the number of DMF filings over the past two decades. This is due to the increasing investments to enhance manufacturing facilities by Asian companies to meet international quality standards. In addition, market players in India are increasingly focusing on achieving compliance with standards laid by various regulatory agencies such as the US FDA, TGA, MHRA, Brazilian Health Regulatory Agency, and SAHPRA. The increasing DMF approvals by regulatory agencies are providing significant growth opportunities for API manufacturers. Such factors will lead to the expansion of the global active pharmaceutical ingredients market at a CAGR of over 6% during the forecast period.

Paradigm shift in API manufacturing
Traditionally, most of the pharmaceutical companies have been relying on their in-house capabilities for the discovery, development, and manufacturing of APIs. However, the captive API manufacturing has seen an overhaul in the last few decades as many pharmaceutical companies are focusing on outsourcing a large share of their research and manufacturing processes to CMOs or other drug manufacturing organizations. The decision to outsource an API depends on several factors, such as industry trends, the cost of acquiring new in-house technologies, and the availability of internal capacity. Outsourcing of API enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing significant efficiencies in the supply chain. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global active pharmaceutical ingredients market during the forecast period 2020-2024, click here.

Competitive Landscape
With the presence of several major players, the global active pharmaceutical ingredients market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.
Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY MANUFACTURING TYPE
• Market segmentation by manufacturing type
• Comparison by manufacturing type
• Captive API – Market size and forecast 2019-2024
• Contract API – Market size and forecast 2019-2024
• Market opportunity by manufacturing type
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Asia – Market size and forecast 2019-2024
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing geriatric population
• Paradigm shift in API manufacturing
• Increasing patent expiries
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amneal Pharmaceuticals Inc.
• Cadila Healthcare Ltd.
• Jazz Pharmaceuticals Plc
• Lupin Ltd.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Vendors: Key offerings
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2019
Exhibit 07: Global market: Size and forecast 2019-2024 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 09: Five forces analysis 2019
Exhibit 10: Five forces analysis 2024
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2019
Exhibit 17: Customer landscape
Exhibit 18: Manufacturing type – Market share 2019-2024 (%)
Exhibit 19: Comparison by manufacturing type
Exhibit 20: Captive API – Market size and forecast 2019-2024 ($ billions)
Exhibit 21: Captive API – Year-over-year growth 2020-2024 (%)
Exhibit 22: Contract API – Market size and forecast 2019-2024 ($ billions)
Exhibit 23: Contract API – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by manufacturing type
Exhibit 25: Market share by geography 2019-2024 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Asia – Market size and forecast 2019-2024 ($ billions)
Exhibit 28: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 29: Top 3 countries in Asia
Exhibit 30: North America – Market size and forecast 2019-2024 ($ billions)
Exhibit 31: North America – Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2019-2024 ($ billions)
Exhibit 34: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: ROW – Market size and forecast 2019-2024 ($ billions)
Exhibit 37: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Cumulative number of DMFs filled 2001-2018
Exhibit 42: Total WLs issued 2010-2014
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Amneal Pharmaceuticals Inc. – Vendor overview
Exhibit 50: Amneal Pharmaceuticals Inc. – Business segments
Exhibit 51: Amneal Pharmaceuticals Inc. – Organizational developments
Exhibit 52: Amneal Pharmaceuticals Inc. – Segment focus
Exhibit 53: Amneal Pharmaceuticals Inc. – Key offerings
Exhibit 54: Amneal Pharmaceuticals Inc. – Key customers
Exhibit 55: Cadila Healthcare Ltd. – Vendor overview
Exhibit 56: Cadila Healthcare Ltd. – Business segments
Exhibit 57: Cadila Healthcare Ltd. – Organizational developments
Exhibit 58: Cadila Healthcare Ltd. – Geographic focus
Exhibit 59: Cadila Healthcare Ltd. – Key offerings
Exhibit 60: Cadila Healthcare Ltd. – Key customers
Exhibit 61: Jazz Pharmaceuticals Plc – Vendor overview
Exhibit 62: Jazz Pharmaceuticals Plc – Business segments
Exhibit 63: Jazz Pharmaceuticals Plc – Organizational developments
Exhibit 64: Jazz Pharmaceuticals Plc – Geographic focus
Exhibit 65: Jazz Pharmaceuticals Plc – Key offerings
Exhibit 66: Jazz Pharmaceuticals Plc – Key customers
Exhibit 67: Lupin Ltd. – Vendor overview
Exhibit 68: Lupin Ltd. – Business segments
Exhibit 69: Lupin Ltd. – Organizational developments
Exhibit 70: Lupin Ltd. – Geographic focus
Exhibit 71: Lupin Ltd. – Key offerings
Exhibit 72: Lupin Ltd. – Key customers
Exhibit 73: Mylan NV – Vendor overview
Exhibit 74: Mylan NV – Product segments
Exhibit 75: Mylan NV – Organizational developments
Exhibit 76: Mylan NV – Geographic focus
Exhibit 77: Mylan NV – Segment focus
Exhibit 78: Mylan NV – Key offerings
Exhibit 79: Mylan NV – Key customers
Exhibit 80: Novartis AG – Vendor overview
Exhibit 81: Novartis AG – Business segments
Exhibit 82: Novartis AG – Organizational developments
Exhibit 83: Novartis AG – Geographic focus
Exhibit 84: Novartis AG – Segment focus
Exhibit 85: Novartis AG – Key offerings
Exhibit 86: Novartis AG – Key customers
Exhibit 87: Pfizer Inc. – Vendor overview
Exhibit 88: Pfizer Inc. – Business segments
Exhibit 89: Pfizer Inc. – Organizational developments
Exhibit 90: Pfizer Inc. – Geographic focus
Exhibit 91: Pfizer Inc. – Segment focus
Exhibit 92: Pfizer Inc. – Key offerings
Exhibit 93: Pfizer Inc. – Key customers
Exhibit 94: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 95: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 96: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 97: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 98: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 99: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 100: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 101: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 102: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 103: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 104: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 105: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 106: Thermo Fisher Scientific Inc. – Vendor overview
Exhibit 107: Thermo Fisher Scientific Inc. – Business segments
Exhibit 108: Thermo Fisher Scientific Inc. – Organizational developments
Exhibit 109: Thermo Fisher Scientific Inc. – Geographic focus
Exhibit 110: Thermo Fisher Scientific Inc. – Segment focus
Exhibit 111: Thermo Fisher Scientific Inc. – Key offerings
Exhibit 112: Thermo Fisher Scientific Inc. – Key customers
Exhibit 113: Validation techniques employed for market sizing
Exhibit 114: Definition of market positioning of vendors



【掲載企業】

Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[有効成分の世界市場:予測及び分析 2020-2024]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆